Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | HTR7 | P34969 | 4/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | PAK4 | O96013 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240671 | 0.83 | CDK4 (0.46) | HTR1AHTR2AHTR6PTGS2KMT2A | |
| SCHEMBL3243542 | 0.82 | HRH3 (0.49) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL3233135 | 0.80 | MAPT (0.59) | KMT2AMEN1MAPTPOLBSLC2A1 | |
| SCHEMBL3240537 | 0.79 | AURKA (0.48) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL3246140 | 0.78 | MAPT (0.58) | KMT2AMEN1MAPTPOLBSLC2A1 | |
| SCHEMBL7015692 | 0.77 | HRH3 (0.67) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL12696468 | 0.76 | PAK4 (0.53) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL30198268 | 0.76 | PAK4 (0.53) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL3244336 | 0.76 | MAPT (0.57) | KMT2AMEN1MAPTPOLBSLC2A1 | |
| SCHEMBL3388226 | 0.76 | HTR1A (0.52) | HTR1ADRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2140864-A2 | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| US-7465750-B2 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2007-11-08 | — | — | US | disclosed |
| US-7220775-B2 | Compound useful for the treatment of neuropathic pain | H. LUNDBECK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | HTR1A 45/4885DRD2 508/4885HTR2A 88/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | HTR1A 45/4885DRD2 508/4885HTR2A 88/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | HTR1A 13/4885DRD2 191/4885HTR2A 18/4885 |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | HTR1A 45/4885DRD2 400/4885HTR2A 85/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | HTR1A 222/4885DRD2 1612/4885HTR2A 286/4885 |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | HTR1A 45/4885DRD2 435/4885HTR2A 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.